Front Row Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Front Row Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.16K	Hold	20	–	–	﹤0.01%	489
2026 Q1	$2.56K	Hold	20	–	–	﹤0.01%	489
2025 Q4	$2.44K	Hold	20	–	–	﹤0.01%	480
2025 Q3	$2K	Hold	20	–	–	﹤0.01%	487
2025 Q2	$1.66K	Hold	20	–	–	﹤0.01%	476
2025 Q1	$1.62K	Hold	20	–	–	﹤0.01%	453
2024 Q4	$1.8K	Hold	20	–	–	﹤0.01%	448
2024 Q3	$1.98K	Hold	20	–	–	﹤0.01%	446
2024 Q2	$1.85K	Hold	20	–	–	﹤0.01%	856
2024 Q1	$1.9K	Hold	20	–	–	﹤0.01%	850
2023 Q4	$1.79K	Hold	20	–	–	﹤0.01%	418
2023 Q3	$1.46K	Hold	20	–	–	﹤0.01%	844
2023 Q2	$2K	Hold	20	–	–	﹤0.01%	830
2023 Q1	$2K	Hold	20	–	–	﹤0.01%	845
2022 Q4	$2K	Hold	20	–	–	﹤0.01%	810
2022 Q3	$2K	Hold	20	–	–	﹤0.01%	843
2022 Q2	$1K	Hold	20	–	–	﹤0.01%	910
2022 Q1	$2K	Hold	20	–	–	﹤0.01%	882
2021 Q4	$2K	Hold	20	–	–	﹤0.01%	896
2021 Q3	$3K	Hold	20	–	–	﹤0.01%	835
2021 Q2	$2K	Hold	20	–	–	﹤0.01%	893
2021 Q1	$3K	Hold	20	–	–	﹤0.01%	835
2020 Q4	$3K	Hold	20	–	–	﹤0.01%	798
2020 Q3	$3K	Hold	20	–	–	﹤0.01%	795
2020 Q2	$2K	Hold	20	–	–	﹤0.01%	885
2020 Q1	$2K	Buy	+20	New	+$1.77K	﹤0.01%	859

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Front Row Advisors's XBI Position: Q2 2026 in Review

Front Row Advisors held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 20 shares worth $3.16K. The position accounts for ﹤0.01% of the portfolio, ranked #489.

Front Row Advisors first reported a position in XBI in Q1 2020 and has held it in 26 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Front Row Advisors held 20 shares of State Street SPDR S&P Biotech ETF worth $3.16K as of Q2 2026.
Front Row Advisors left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Front Row Advisors's portfolio in Q2 2026, its #489 holding.
Front Row Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2020 and has held it in 26 quarters since.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Front Row Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.